Belnacasan

N/A

Report date: 2022/01/14 17:48:58
NME

Base Information

Drug NameBelnacasan
Drug Alias NameBelnacasanum贝那卡生贝那卡桑UNII-00OLE78529VX-765
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCaspase-1 inhibitors
TargetsCaspase-1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)PsoriasisEpilepsies, Partial +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesMedstar Health
Inactive CompaniesVertex Pharmaceuticals Incorporated
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsPsoriasisEpilepsies, PartialEpilepsy

Other Information

ATC CodeN/A
Related LinksKEGG